ALLMedicine™ Hepatitis D Center

Feb 18th, 2021 - With extensive research on the pathogenesis and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, the current treatment of interferon and nucleoside or nucleotide analogues provides reasonable control of viral replicatio...

Feb 16th, 2021 - Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus (HDV) infections, and progeria and progeroid laminopathies. The dru...

Jan 23rd, 2021 - The global scenario of hepatitis D is changing with the widespread implementation of vaccination against hepatitis B. In high-income countries that achieved optimal control of HBV, the epidemiology of hepatitis D is dual, consisting of an ageing c...

Dec 15th, 2020 - Chronic HDV infection often is associated with aggressive form of liver disease, compared to chronic HBV mono-infection. However, chronic HDV treatment is challenging because currently there is no approved regimen for affected patients. While stan...

Dec 4th, 2020 - Chronic hepatitis D (CHD), a global health problem, manifests as the most severe form of viral hepatitis. The causative agent, HDV, is the smallest known human virus; it replicates its circular single-stranded RNA genome in the nucleus of hepatocy...

Feb 18th, 2021 - With extensive research on the pathogenesis and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, the current treatment of interferon and nucleoside or nucleotide analogues provides reasonable control of viral replicatio...

Feb 16th, 2021 - Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus (HDV) infections, and progeria and progeroid laminopathies. The dru...

Jan 23rd, 2021 - The global scenario of hepatitis D is changing with the widespread implementation of vaccination against hepatitis B. In high-income countries that achieved optimal control of HBV, the epidemiology of hepatitis D is dual, consisting of an ageing c...

Dec 15th, 2020 - Chronic HDV infection often is associated with aggressive form of liver disease, compared to chronic HBV mono-infection. However, chronic HDV treatment is challenging because currently there is no approved regimen for affected patients. While stan...

Dec 4th, 2020 - Chronic hepatitis D (CHD), a global health problem, manifests as the most severe form of viral hepatitis. The causative agent, HDV, is the smallest known human virus; it replicates its circular single-stranded RNA genome in the nucleus of hepatocy...

Nov 12th, 2020 - NEW YORK (Reuters Health) - Several risk factors associated with hepatitis D virus (HDV) infection can be used to identify people who should be screened, researchers report. "It was interesting to find that the risk factors that were identified in...

Dec 19th, 2019 - NEW YORK (Reuters Health) - Hepatitis delta virus (HDV) infection, which occurs only as a co-infection with acute hepatitis B (HBV) or a superinfection with chronic HBV, is associated with higher healthcare utilization and costs than HBV alone, a ...

Nov 8th, 2019 - BOSTON – For most patients with chronic hepatitis D virus (HDV) infection, combination therapy with lonafarnib, ritonavir, and peginterferon may significantly decrease viral loads, based on interim results from the phase IIa LIFT trial. After 6 mo.

Apr 19th, 2018 - What is the hepatitis virus? Well, the hepatitis virus invades liver cells and causes inflammation in the liver tissue. Five hepatitis viruses are recognized: hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. They all have sligh...

Aug 1st, 2016 - In Reply: We thank Dr. Homler for bringing hepatitis D as a potential cause of acute liver failure to our attention.